Cargando…
Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare Communications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873121/ https://www.ncbi.nlm.nih.gov/pubmed/24392296 http://dx.doi.org/10.1007/s13554-012-0001-6 |
_version_ | 1782297061031411712 |
---|---|
author | Reiff, Andreas |
author_facet | Reiff, Andreas |
author_sort | Reiff, Andreas |
collection | PubMed |
description | With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA. |
format | Online Article Text |
id | pubmed-3873121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer Healthcare Communications |
record_format | MEDLINE/PubMed |
spelling | pubmed-38731212014-01-02 Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment Reiff, Andreas Biol Ther Review With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA. Springer Healthcare Communications 2012-02-01 /pmc/articles/PMC3873121/ /pubmed/24392296 http://dx.doi.org/10.1007/s13554-012-0001-6 Text en © Springer Healthcare 2012 https://creativecommons.org/licenses/by-nc/4.0/ Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Review Reiff, Andreas Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title | Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title_full | Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title_fullStr | Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title_full_unstemmed | Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title_short | Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment |
title_sort | treatment of systemic juvenile idiopathic arthritis with tocilizumab - the role of anti-interleukin-6 therapy after a decade of treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873121/ https://www.ncbi.nlm.nih.gov/pubmed/24392296 http://dx.doi.org/10.1007/s13554-012-0001-6 |
work_keys_str_mv | AT reiffandreas treatmentofsystemicjuvenileidiopathicarthritiswithtocilizumabtheroleofantiinterleukin6therapyafteradecadeoftreatment |